CDT Equity welcomes interim U.S. policy supporting compounded peptide access
CDT•CDT Equity welcomed an interim HHS policy limiting enforcement against qualifying providers compounding six specified peptides, subject to regulatory conditions. CEO James Bligh called it a positive development for the company's investment in Pep'd; the peptides lack FDA approval.
1. Policy welcomes compounding
CDT Equity welcomed an HHS policy limiting enforcement against qualifying providers compounding six specified peptides, subject to regulatory conditions. CEO James Bligh called the interim policy a positive development for the company's investment in Pep'd, a U.S. peptide and telehealth company; the covered peptides lack FDA approval.
